Advancing Antibiotic Selection for Common Outpatient Infections
- Speaker:
- Eric Wombwell, PharmD, BCIDP
- Duration:
- 2 Hours 03 Minutes
- Format:
- Audio and Video
- Copyright:
-
Mar 25, 2022
- Product Code:
- POS078434
- Media Type:
- Digital Seminar
Description
New research, clinical practice guidelines, and bacterial resistance continues to alter best practice for use of antibiotics. This session will emphasize results from recent research publications that demonstrate opportunities for enhanced antibiotic use to optimize patient outcomes. Dr. Wombwell, PharmD and Board Certified Infectious Disease Pharmacist, will draw attention to clinical situations that antibiotics are overprescribed, unnecessarily used, inappropriately dosed and underutilized in the treatment of infections.
Credit
Handouts/Brochure
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - Advancing Antibiotic Selection (4.8 MB) | 60 Pages | Available after Purchase | |
| Transcript - Advancing Antibiotic Selection (112.1 KB) | 22 Pages | Available after Purchase | |
| Manual - Advancing Antibiotic Selection - French (4.8 MB) | 60 Pages | Available after Purchase | |
| Transcript - Advancing Antibiotic Selection - French (112.1 KB) | 22 Pages | Available after Purchase | |
| Manual - Advancing Antibiotic Selection - Italian (4.8 MB) | 60 Pages | Available after Purchase | |
| Transcript - Advancing Antibiotic Selection - Italian (112.1 KB) | 22 Pages | Available after Purchase | |
| Manual - Advancing Antibiotic Selection - German (4.8 MB) | 60 Pages | Available after Purchase | |
| Transcript - Advancing Antibiotic Selection - German (112.1 KB) | 22 Pages | Available after Purchase | |
| Manual - Advancing Antibiotic Selection - Spanish (4.8 MB) | 60 Pages | Available after Purchase | |
| Transcript - Advancing Antibiotic Selection - Spanish (112.1 KB) | 22 Pages | Available after Purchase |
Speaker
Eric Wombwell, PharmD, BCIDP Related seminars and products
Dr. Eric Wombwell is a board-certified infectious diseases pharmacist and clinical associate professor for the Department of Pharmacy Practice and Administration at the University of Missouri – Kansas City, School of Pharmacy. Eric completed his PharmD degree at the University of Missouri Kansas City, followed by an ASHP accredited pharmacy practice residency at the Kansas City VA Medical Center. Following residency, he accepted a full-time non-tenured clinical faculty position at the University of Missouri – Kansas City, School of Pharmacy. His teaching responsibilities include infectious diseases topics throughout the curriculum. Eric also has a clinical appointment at Centerpoint Medical Center rounding with the infectious diseases consult team and supporting antimicrobial stewardship efforts at the facility.
Eric is regularly published in pharmacy and infectious diseases research and is frequently invited to deliver continuing education presentations locally and nationally to various health-professional audiences. He is recognized for excellence in teaching through various awards, including the “Missouri Pharmacist Association – UMKC Faculty Member of the Year”, and the “University of Missouri – Kansas City Provost’s Award for Excellence in Teaching”.
Speaker Disclosures:
Financial: Eric Wombwell has an employment relationship with the University of Missouri. He receives a speaking honorarium, recording royalties, and a consulting fee from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Eric Wombwell is a member of the Society of Infectious Diseases Pharmacists, the Missouri Pharmacists Association, American Association of Colleges of Pharmacy, Infectious Diseases Society of America, and Centerpoint Medical Center.
Additional Info
Access for Self-Study (Non-Interactive)Access never expires for this product.
Questions?
Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info
Objectives
- Evaluate beta-lactam reaction histories to makes evidence-based decisions on the need to avoid beta-lactam therapies.
- Develop risk factor–based empiric antibiotic regimens for patients with suspected community-acquired pneumonia.
- Conclude which clinical scenarios require MRSA coverage for skin infections.
- Formulate effective evidence-based therapies for Clostridioides difficile infections.
- Choose cost-effective antibiotic therapies that minimize risk for adverse effects.
Outline
Penicillin Allergy- Side effect vs. allergy
- Reassessing allergy statistics
- Cephalosporin cross-sensitivity
- Allergy history and antibiotic indication-based recommendations
- Assess 2019 ATS/IDSA guidelines
- Review EPIC study
- Streptococcus pneumonia resistance
- Evaluate and contrast oral therapies for CAP
- Assessing Streptococcus vs. Staphylococcus
- When is MRSA therapy necessary?
- Comparison of oral MRSA therapies
- NSAID adjunct
- Vancomycin vs. Fidaxomicin
- Managing recurrence
- Probiotic assessment
Target Audience
- Nurses
- Nurse Practitioners
- Physicians
- Physicians Assistants
Reviews
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.
PESI Mobile App
Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world’s best instructors, and complete your CE requirements anywhere, anytime, at your own pace.
Please wait ...